Objective: We have shown previously that cutting or loading articular cartilage resulted in a fibroblast growth factor-2 (FGF-2) dependent activation of the extracellularly regulated kinase (ERK), and induction of a number of chondrocyte regulatory proteins including tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases 1 and 3. An extracellular matrix-bound pool of FGF-2 was apparent, which could be (2):526e33). Our objectives were to determine where FGF-2 was stored in articular cartilage, to which proteoglycan it was bound, and to elucidate its role in chondrocyte mechanotransduction.
Introduction
The ability of the cells of articular cartilage to sense and respond to mechanical force is undisputed. Not only is it well accepted that excessive mechanical stress increases the risk of developing osteoarthritis, but intermittent loads associated with modest weight bearing activity appear to be important for anabolic tissue responses. This is illustrated by the observation that 50% of knee cartilage volume is lost in patients within 6 months of sustaining a spinal cord injury 1 , and a recent imaging study in which patients, randomised to moderate exercise, demonstrated increased glycosmaninoglycan (GAG) content in their knee cartilage using delayed gadolinium-enhanced magnetic resonance imaging 2 . These clinical responses are consistent with data showing regulation in vitro of matrix proteins such as aggrecan and type II collagen, as well as matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), in response to loading cartilage explants and chondrocytes 3e7 . It should be stressed that regulation is complex, and is affected by the frequency, magnitude and duration of the applied load 8e10 . Surprisingly little is known about how mechanical signals are transduced through cartilage to change chondrocyte gene expression. Integrins are favoured mechanical transducers in cartilage: through their extracellular domains they form multiple connections with the extracellular matrix (reviewed in Ref. 11 ), and intracellularly, they are thought to recruit signalling molecules (they have no intrinsic signalling activity themselves) to activate signalling pathways 12e14 . Indeed, hyperpolarisation of human articular chondroctyes in response to stretch, and a transforming growth factor (TGF) beta-dependent incorporation of 35 SO 4 in compressed monolayer chondrocytes were both inhibited by alpha 5 beta 1 integrin blockade 15e17 . Intracellular signalling events in response to loading chondrocytes also include activation of ion-and stretch-activated ion channels: intracellular calcium flux was detected in chondrocytes in agarose in response to cyclical load 18 , and blocking stretch-activated channels, and calcium flux with gadolinium or nifedipine, respectively, inhibited the biological responses to stretch of primary chondrocytes seeded in a collagen matrix 19 . Voltageactivated calcium channels and epithelial sodium channels have been shown to co-localise with beta 1 integrin in 'mechanoreceptor complexes' in loaded limb bud chondrocytes 20 . It is also possible that tissue growth factors act as mechanotransducers. Previously, we found that there was an fibroblast growth factor (FGF)-dependent activation of the extracellularly regulated kinase (ERK) upon cutting or loading articular cartilage 7, 21 . FGF-2 was present in the extracellular matrix of articular cartilage and was released following treatment with the heparin degrading enzyme heparitinase, suggesting that it was bound to a heparan sulphate proteoglycan (HSPG). Perlecan, originally described as the proteoglycan of basement membranes, is highly expressed in cartilage 22e24 and is therefore a good candidate for sequestering FGF-2.
We hypothesised that in articular cartilage FGF-2 is stored in the extracellular matrix bound to perlecan, and that it is this pool of FGF that mediates FGF receptor activation upon mechanical stimulation. Here we show that perlecan is an abundant HSPG in human articular cartilage, and that perlecan and FGF-2 co-localise within the pericellular matrix of articular cartilage. Activation of ERK in loaded alginate encapsulated chondrocytes is dependent upon the presence and concentration of pericellular FGF-2.
Methods

TISSUE
Porcine articular cartilage was from the metacarpophalangeal joints, and knee joints of 3-to 6-month-old pigs obtained from a local abattoir 4e8 h post-slaughter. Normal human articular cartilage was from the knee joint of individuals (ages 55 and 60 years) undergoing surgery at the RNOH, Stanmore, for removal of bone tumours.
MATERIALS
Antibodies to perlecan (rat monoclonal, MAB1948) were obtained from Chemicon International (Temecla, CA). FGF-2 antibodies (mouse monoclonal, 05-118), and phosphotyrosine clone 4G10 were from Upstate Cell signalling solutions, Milton Keynes. Collagen type VI anti-serum (rabbit) was kindly provided by Thomas Aigner, Erlangen, Germany. Monoclonal antibodies to beta 1 integrin were purchased from Biohit, Helsinki, Finland. Basic FGF was obtained from Peprotec, London, insulin growth factor (IGF)-1 was from R and D Systems, MN. Heparitinase I, Chondroitinase ABC and the heparan sulphate (HS) stub antibody (3G10) (Seikagaku, Japan) were purchased through Calbiochem, Nottingham, UK. For heparitinase, enzyme was reconstituted upon arrival, aliquotted, then re-lyophilised and stored at À70 C until required. SB402451 (also known as PD173074) 41 was kindly provided by Stephen Skaper, Glaxo Wellcome. All other reagents including hyaluronidase and Insulin Transferrin Selenium (ITS) þ 1 liquid media were purchased from Sigma, UK.
CONFOCAL MICROSCOPY
Six-micrometre frozen sections were cut onto Surgipath snowcoat Xtra slides, air dried for 1 h and then left for a further hour at 60 C to ensure tissue adherence. Slides were fixed in acetone for 10 min. Sections were pre-treated with hyaluronidase for 1 h (0.01% hyaluronidase/tris-buffered saline at 37 C) with or without heparitinase (10 mu/ml), blocked with 5% bovine serum albumin/1% goat serum/ phosphate-buffered saline (PBS) for 1 h at 37 C, then incubated for a further 1 h at 37 C with antibodies to perlecan (1:1000), FGF-2 (1:1000), type VI collagen (1:5000), beta 1 integrin (1:1000), heparan sulphate stub (3G10) (1:1000) either alone or in combination. Sections were washed with PBS three times, then incubated for 1 h with secondary fluorescein iso-thiocyanate (FITC) labelled antibodies (Alexa 488-conjugated anti-mouse IgG and Alexa 568-conjugated anti-rat IgG). Sections were further washed and mounted. Fluorescence signals were detected by Ultraview confocal microscopy (PerkineElmer, 60Â oil immersion lens).
IMMUNOHISTOCHEMISTRY
For perlecan/FGF-2 staining, 5-mm frozen sections were prepared as above. Sections were blocked with 10% normal serum and were incubated with primary antibodies to perlecan (1:1000) or FGF-2 (1:1000). Antigens were visualised using streptavidin conjugated peroxidase (ABC kit, Vector) according to the manufacturer's recommendations.
IMMUNOSTAINING OF ALGINATE ENCAPSULATED CHONDROCYTES
Ten alginate beads were dissolved in ethylenediaminetetraacetic acid (EDTA) (100 ml, 50 mM), washed in NaCl (150 mM) and then resuspended in NaCl (20 ml) and loaded onto Lab-Tek II chamber slides (Nalge Nunc Int, Denmark). The slide was air dried, fixed in methanol for 15 min and then stained as above.
PURIFICATION OF PERLECAN AND AGGRECAN
Perlecan and aggrecan were purified from batches of 10 g of articular knee cartilage. Tissue was dissected into a 50-ml falcon and washed three times with sterile PBS. A total of 30 ml of 6 M GnHCl was added to the tissue bringing the volume up to 45 ml, and final concentration to 4 M GnHCl. Tissue was left rotating at 4 C for 48 h. Insoluble material was removed by centrifugation. Purification was as described by Govindraj et al. 28 , using dot blot to confirm position of proteins. From 10 g of starting material, assuming 99% purity, 0.429 mg of perlecan and 56.42 mg of aggrecan were obtained. PLASMON following addition of purified perlecan or aggrecan at equimolar concentrations (based on core MW). The cuvette was washed with 4 M GnHCl briefly between washes to dissociate perlecan from FGF-2. Similar analyses were performed on material that had been previously exchanged into buffer (NaCl 150 mmol/CaCl 2 5 mmol, pH 6.2), then treated with either heparitinase (2 m/ml) or chondroitinase ABC (10 m/ml) at 37 C for 1 h.
ALGINATE ENCAPSULATED CHONDROCYTES
Chondrocytes were isolated from porcine metacarpophalangeal joints as previously described 21 . Cells were washed in 150 mM NaCl then resuspended in 1.2% alginate (in 150 mM NaCl) at a density of 5 million cells per ml. The suspension was drawn up into a 10 ml syringe and cells dropped through a 25-gage needle into calcium chloride (102 mM) to form beads. Beads were left to harden for 15 min, washed twice in Dulbecco's Modified Eagle's Medium (DMEM) and then transferred to 24 well plates (5 million cells per well/approximately 70 beads). The beads were cultured in 10% foetal calf serum (FCS) for at least 3 weeks to allow matrix to be laid down. In some cultures, FGF-2 (5 ng/ml) was added after 2 weeks for 3 days and then washed out.
On the morning of the loading experiment, to create the alginate 'plug', beads from individual wells were transferred to Transwell Permeable Supports (pore size: 3.0 mm, diameter 12 mm, Corning, Inc.) and immersed in 1.5 ml of calcium chloride (102 mM) in 12 well plates. 1.2% alginate (approx 300 ml) was added to the Transwell, and further calcium chloride was added to the top of the well. Plugs were left for 2 h at room temperature before removing them from the Transwell and washing them back into serum-free DMEM.
LOADING ALGINATE PLUGS AND CARTILAGE EXPLANTS
Alginate plugs were serum starved for 2 h prior to loading in the presence or absence of the FGFR inhibitor, SB402451 (48 h pre-incubation). Individual plugs were placed between two polyethylene frits (100 mm pore, 15 mm diameter, Kinesis) in a 6 ml bijou and covered with 1 ml DMEM (with or without SB402451). Plugs were loaded using a purpose build pneumatically driven loading rig (for illustration see Fig. 1 ), from an original design by Richard Aspden, Aberdeen 4 . The rig was housed within a humidified incubator (37 C, 20% O 2 , 5% CO 2 ). In essence, loading was achieved by compressed air which raised the lower platform upon which the tissue samples were sitting and in doing so lifted the loading rod with attached weights. Load was thus transmitted through the tissue. The loading waveform was square, but up and down ramp speeds were slowed to so as to create a sinusoid-like waveform. The loading rod was in contact with the tissue at the start of the experiment, in order to minimise impact. Loads delivered to alginate plugs were low: 160 g (the weight of the loading rod), which equated to 0.01 MPa. The amount of strain measured following a 2 min cyclical load was in the order of 25%. After 2 min of confined loading (0.5 Hz) the plug was maintained at 37 C for 30 min and then was transferred onto ice. Medium was replaced with EDTA (50 mM in 150 mM NaCl with 2% Na 3 VO 4 ) to dissolve the alginate. Chondrocytes were centrifuged, washed with PBS, then lysed with a dissociative lysis buffer containing protease inhibitors as described previously 7 . For cartilage explants, tissue was loaded cyclically for 2 min with 1000 g, equating to 0.13e0.2 MPa, depending upon the size of the explant (25e49 mm   2 ). The strain, as measured using a Draper external micrometer was approximately 5%. Tissue was left at 37 C for 30 min then lysed as above. Lysates were immunoblotted for phosphoERK and reprobed for total ERK as before 21 . Some plugs/explants were stimulated with recombinant FGF-2 (100 ng/ml), or with interleukin-1 (IL-1) (100 ng/ml) for 30 min at 37 C.
Results
PERLECAN IS AN ABUNDANT HSPG IN ADULT HUMAN ARTICULAR CARTILAGE
Having previously established that FGF-2 was sequestered in the matrix of articular cartilage attached to HS 21 , we sought to determine where the abundant HSPGs were in the tissue. Human articular cartilage sections were first treated with either heparitinase or with control buffer for 1 h. Sections were stained with an antibody against the HS stub generated by heparitinase treatment. Prior to treatment with heparitinase (control), little in the way of immunoreactive material was detected in the extracellular matrix, however, following treatment with heparitinase, strong staining around individual chondrocytes was detected [ Fig. 2(A) , HS stub, heparitinase treated]. Pericellular staining for the HS proteoglycan perlecan has been described in a number of cartilaginous tissues including ovine stifle joint articular cartilage 22e25 . Staining the sections for perlecan showed precise co-localisation of perlecan and the HS stub by confocal microscopy, suggesting that perlecan was the most abundant HSPG in articular cartilage. At this level of detection, it was not possible to discern cell surface HSPG distinct from perlecan [ Fig. 2(A) , Perlecan and Merged].
To confirm that perlecan was in the true pericellular matrix, rather than on the cell surface or in the territorial matrix, further confocal microscopy was performed. Immunostaining for perlecan and a cell surface antigen, beta 1 integrin, revealed distinct spatial separation with no evidence of colocalisation [ Fig. 2(B) ], indicating that perlecan was indeed outside the cell. Moreover, staining for perlecan and type VI collagen, a known pericellular matrix protein 26 , revealed that they only partly co-localised, but that both proteins lay within the same anatomical matrix compartment [ Fig. 2(C) ].
FGF-2 CO-LOCALISES WITH PERLECAN IN HUMAN ARTICULAR CARTILAGE
We next sought to determine whether FGF-2 and perlecan co-localised in the pericellular matrix. Immunohistochemistry of adult femoral chondylar cartilage revealed a distinct pattern of staining which was similar for both FGF-2 and perlecan [ Fig. 3(A) ]. In the mid zone of cartilage, staining for both was pericellular. Interestingly, in the superficial zone, perlecan and FGF-2 were distributed in a distinct pattern where multiple cells were encompassed within laminar bands of staining running parallel to the articular surface. This superficial pattern of staining was approximately six to eight cells deep from the articular surface and was present in normal adult articular cartilage from 
PERLECAN PURIFIED FROM PORCINE ARTICULAR CARTILAGE BINDS TO RECOMBINANT FGF-2 IN VITRO
To verify the immunohistochemistry, perlecan was purified from porcine articular cartilage (see Methods), and surface plasmon resonance was used to determine that it bound recombinant FGF-2 in vitro. Aggrecan purified from articular cartilage was used as a negative control. Both samples were immunoblotted to confirm proteoglycan purity (data not shown). Immobilised FGF-2 bound to perlecan, but not to equimolar concentrations (by core molecular weight) of aggrecan [ Fig. 4(A) ]. In a separate experiment, binding was shown to be dependent upon heparan sulphate as prior treatment of perlecan with heparitinase abolished binding [ Fig. 4(B) ]. Some loss of protein was apparent in the heparitinase and buffer treated samples which most likely reflected losses during buffer exchange. Prior treatment of perlecan with chondroitinase did not affect binding to FGF-2 indicating that the interaction between perlecan and FGF-2 was mediated by heparan sulphate and not sulphated proteoglycan per se (data not shown).
ALGINATE ENCAPSULATED PORCINE CHONDROCYTES ACCUMULATE PERICELLULAR PERLECAN AND FGF-2
To investigate the source and function of pericellular FGF-2, we first looked to see whether isolated porcine articular chondrocytes would accumulate a pericellular matrix in culture. Porcine chondrocytes were encapsulated into alginate beads, then cultured for 3 weeks in either 10% serum or ITS, a synthetic serum substitute containing no FGF-2. At the end of the culture period, cells were released by dissolving the alginate, and immunostained for perlecan or FGF-2. Freshly isolated chondrocytes, that had been cultured in alginate for only 2 days had little detectable staining for either perlecan or FGF-2 (Fig. 5, control) , however, alginate encapsulated cells which had been cultured in 10% serum for 3 weeks demonstrated significant staining for both FGF-2 and perlecan (Fig. 5, FCS) . Cells grown in ITS for 3 weeks showed less staining for perlecan, likely due to the absence of TGF beta, present in serum, but still accumulated significant amounts of FGF-2 (Fig. 5, ITS) . The absence of FGF-2 in ITS culture medium means that the FGF-2 must be made and secreted by the chondrocyte. How the chondrocyte secretes FGF-2, in the absence of a signal peptide, is subject to much debate, and is beyond the scope of this paper.
MECHANICAL LOADING OF ALGINATE ENCAPSULATED CHONDROCYTES INDUCES AN FGF-DEPENDENT ACTIVATION OF ERK
We have previously shown that there is an FGF-2 dependent activation of ERK when articular cartilage is cut or loaded 7, 21 . In these experiments, cyclical loading for 2 min was sufficient to activate the ERK pathway at a variety of modest, non-injurious, loads. To see if loading would activate ERK in alginate encapsulated chondrocytes, cells which had been cultured for 4 weeks in 10% serum, were made into plugs, then loaded cyclically for 2 min (0.5 Hz, 0.01 MPa). Plugs were maintained at 37 C for the times specified, then dissolved on ice. Cells were lysed and immunoblotted for phosphorylated, and then total ERK. ERK activation was apparent upon loading, but not in the unloaded controls, and persisted for 6 h following load [ Fig. 6(A) 'encapsulated chondrocytes' ]. This prolonged activation of ERK following a 2 min load was similar to that seen on loading rested cartilage explants (0.5 Hz, 0.13 MPa) [ Fig. 6(A) 'Explants']. In both instances, ERK activation had returned to baseline by 15 h (data not shown). In another set of experiments we were also able to Fig. 4 . Perlecan purified from articular cartilage binds FGF-2 in vitro. FGF-2 was coupled to the IASYS sensor surface (see Methods). 0.8 mg (5 ml in 4 M GnHCl) of perlecan (solid line) or 1.6 mg (5 ml in 4 M GnHCl) of aggrecan (dashed line) was diluted in PBS (95 ml) and added to the sensor surface. Binding (arc seconds) was observed (A). In a separate experiment, 0.8 mg of perlecan was exchanged into buffer (NaCl 150 mmol/CaCl 2 5 mmol, pH 6.2) then incubated with either buffer alone or 2 mu/ml heparitinase for 1 h at 37 C. Buffer treated perlecan (solid line), or heparitinase treated perlecan (dashed line) were added to the cuvette in PBS. Binding was observed when each sample (5 ml in 95 ml PBS) was added to the cuvette sensor surface (B).
human cartilage were taken and incubated with primary antibodies to FGF-2 and perlecan as above. Sections were washed and incubated with secondary FITC labelled antibodies (1:2000) . Fluorescence signals were detected either alone ('Perlecan' and 'FGF-2'), or 'merged' by Ultraview confocal microscopy (C). Bar ¼ 20 mm. Fig. 6 . An FGF-dependent activation of ERK occurs when alginate encapsulated chondrocytes are loaded. Alginate encapsulated chondrocytes which had been cultured in 10% serum for 3 weeks were made into alginate plugs (see Methods), then serum starved for 2 h. Plugs were then left untreated (À) or loaded (þ) for 2 min (0.01 MPa, 0.5 Hz). After 30 min chondrocytes were dissolved from the alginate (50 mM EDTA in 150 mM NaCl with 2% Na 3 VO 4 ) on ice and lysates generated to immunoblot for phosphorylated ERK. The blot was stripped and reprobed for total ERK (A, Encapsulated chondrocytes). Similar experiments were performed with porcine knee articular cartilage explants loaded for 2 min (0.13 MPa, 0.5 Hz) (A, explants), and with alginate encapsulated chondrocytes grown for 3 weeks in ITS (B). To test the FGF-2 dependence of ERK activation upon loading, alginate encapsulated chondrocytes which had been cultured for 4 weeks in 10% serum were pre-incubated with either medium alone (control) or SB402451 (250 nM) for 48 h. Plugs were prepared as above, and were treated with either serum-free medium (c), IL-1 (100 ng/ml), FGF-2 (100 ng/ml) or were loaded cyclically for 2 min (0.01 MPa, 0.5 Hz) (load). After 30 min, lysates were generated as above for phosphorylated ERK and total ERK immunoblots (C). Rested cartilage explants were cyclically loaded with 0.032, 0.01 and 0.002 MPa for 2 min. Explants were lysed as above and immunoblotted for phosphorylated, then total ERK (D).
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Fig . 5 . Accumulation of pericellular FGF-2 and perlecan in alginate encapsulated chondrocytes. Chondrocytes were digested from porcine articular cartilage and encapsulated into alginate beads (see Methods). Beads were cultured in 10% serum or ITS for 3 weeks. In addition, some freshly isolated chondrocytes were encapsulated into alginate, and cultured for 2 days in serum. At the end of the culture period, beads were dissolved in EDTA, resuspended in a small volume of NaCl (150 mM) and then allowed to adhere to Lab-Tek II chamber slides. Cells were immunostained for perlecan (1:1000) or FGF-2 (1:1000) using the peroxidase based ABC kit, as before. Bar ¼ 100 mm.
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demonstrate activation of ERK when alginate encapsulated chondrocytes grown in ITS for 3 weeks were loaded [ Fig. 6(B) ]. ERK activation in response to chondrocyte loading appears to be highly sensitive. To study this further we also determined the minimum load able to activate this pathway. We cyclically loaded resting cartilage explants for 2 min with 0.032, 0.01 or 0.002 MPa. ERK activation was apparent when cartilage was loaded at 0.032 and 0.01 MPa, but not at 0.002 MPa [ Fig. 6(D) ]. Interestingly, in this and other experiments, we have not been able to detect any differences in the magnitude of ERK response with increasing loads. This suggests that rather than there being a graded response to load, there is a threshold above which ERK activation occurs.
To confirm that the ERK activation upon loading alginate encapsulated chondrocytes was due to FGF-2, we repeated the experiment in the presence of the FGF receptor inhibitor SB402451 (250 nM). This inhibitor has been validated previously and is highly specific for FGFRs at this concentration 21, 41 . Chondrocytes, encapsulated into alginate and cultured for 4 weeks in 10% serum were made into plugs. Plugs were either left untreated (C), stimulated with IL-1 (100 ng/ml), FGF-2 (100 ng/ml), or were cyclically loaded for 2 min (0.5 Hz, 0.01 MPa). All samples were left at 37 C for a total of 30 min. Chondrocytes were lysed and immunoblotted as before. In the absence of the FGFR inhibitor, ERK was activated by both exogenous FGF-2 and by loading, and weakly by IL-1. In the presence of the FGFR inhibitor the responses to FGF-2 and loading were strongly suppressed, whilst the response to IL-1, which activates ERK via a separate pathway, was unaffected [ Fig. 6(C) ]. The results indicate that the activation of ERK upon loading alginate encapsulated cells was largely dependent upon FGF-2.
ERK ACTIVATION UPON LOADING IS DEPENDENT UPON THE PERICELLULAR CONCENTRATION OF FGF-2
To confirm that the ERK activation upon loading alginate encapsulated chondrocytes was dependent upon pericellular FGF-2, rather than release of intracellular growth factor, we generated chondrocytes with differing concentrations of pericellular FGF-2 through manipulation of the culture conditions. By this means we generated cells with no detectable immunostaining for pericellular FGF-2 (freshly isolated cells as before), cells which had been cultured for 3 weeks in 10% serum which demonstrated modest FGF-2 staining, and cells which had been cultured for 3 weeks in 10% serum but which had also received exogenous recombinant FGF-2 for 3 days in week 2 of culture. These cells accumulated significantly more pericellular FGF-2 by immunostaining [ Fig. 7(A) ]. When these cells were made into plugs and loaded, ERK activation occurred only in those cells that exhibited pericellular staining for FGF-2, i.e. those cultured for 3 weeks in serum [ Fig. 7(B) , '10% serum' and '10% serum/FGF-2']. Moreover, the ERK response was increased in those cells where the pericellular concentration of FGF-2 was greatest, i.e., those cultured with recombinant FGF-2 [ Fig. 7(B) , '10% serum/FGF-2']. Cells that had been freshly isolated from cartilage, and which showed no immunostaining for FGF-2 failed to become activated upon loading [ Fig. 7(B) , 'control']. All three sets of chondrocytes were able to activate ERK normally in response to recombinant FGF-2 indicating that FGFR expression was not affected by the different culture conditions. There was also no indication that the cell numbers were different between the FGF treated and untreated cells as judged by total ERK levels, although total ERK levels for freshly isolated cells were consistently lower.
PROTEIN TYROSINE PHOSPHORYLATION OF PROTEINS FOLLOWING LOADING IS MAINLY FGF DEPENDENT
Thus far, we have demonstrated that the ERK activation upon loading articular chondrocytes is FGF dependent. To determine whether other pathways might also be involved in chondrocyte responses to loading, we studied the protein tyrosine phosphorylation patterns of chondrocytes which had been stimulated by FGF-2 or loading, in the presence or absence of the FGFR inhibitor. IL-1 was also used to control for the specificity of the inhibitor. Cell lysates were prepared after 5, 15 and 30 min following stimulation, then electrophoresed and immunoblotted with a phosphotyrosine antibody. The blots were stripped and reprobed firstly for phosphorylated ERK, then total ERK. Upon stimulation with IL-1, FGF-2, or by loading a number of cellular proteins showed increased tyrosine phosphorylation compared to control at 5, 15 and 30 min. Fig. 8A shows the 15 min time point. Close inspection of the autoradiographs showed changes in at least 15 bands, ranging from 40 to 150 kDa. The pattern of band induction was similar between FGF-2 and loading, although IL-1 also caused tyrosine phosphorylation of many of the same proteins. In the presence of the FGFR inhibitor, the increase in protein tyrosine phosphorylation upon loading or FGF-2 stimulation was markedly suppressed indicating that most of the early tyrosine phosphorylation events upon loading were FGF dependent. The IL-1 response was not blunted by the presence of the FGFR inhibitor. A phosphorylated band/s migrating at approximately 150 kDa was strongly induced by loading or IL-1, but was not suppressed by the FGFR inhibitor, indicating that additional, FGF-independent, pathways may also be activated upon loading. Of the expected phosphorylated proteins, the FGFR was not clearly visible as a discreet phosphorylated band (expected to run at 110 kDa). Phosphorylated ERK was apparent only on stripping and reprobing the membrane [ Fig. 8(B) ]. As expected, ERK activation upon stimulation with FGF-2 or loading was inhibited by the FGFR inhibitor. At 15 min, ERK activation upon IL-1 stimulation was barely detectable. Even sample loading was confirmed by total ERK levels [ Fig. 8(C) ].
Discussion
We have shown that in articular cartilage FGF-2 binds to the abundant HSPG perlecan, and that FGF-2 and perlecan co-localise within the pericellular matrix of human and porcine chondrocytes. We have demonstrated that chondrocytes encapsulated in alginate are able to lay down a pericellular matrix, and have uncovered a role for pericellular FGF-2 in chondrocyte mechanotransduction.
By electron microscopy, the pericellular matrix of articular cartilage is seen as a relatively lucent zone around chondrocytes, devoid of fibrillar collagens. By immunohistochemistry, this region is rich in type VI collagen and excludes type II collagen 26 . Perlecan is known to be a pericellular matrix protein in developmental and ovine articular cartilages 23e25 , and is up-regulated in osteoarthritis 27 . We have confirmed its pericellular localisation in adult human cartilage and also shown that it binds and co-localises with FGF-2. In the superficial layer of human cartilage, perlecan and FGF-2 formed laminar bands, which ran parallel to the articular surface, and by inference, perpendicular to Fig. 7 . ERK activation upon loading is dependent upon pericellular FGF-2. Alginate encapsulated chondrocytes were generated in three different ways: cells which had been freshly isolated and encapsulated for 2 days only (control), cells which had been encapsulated and cultured in 10% serum for 3 weeks (10% serum), and cells which had been encapsulated and cultured in 10% serum for 3 weeks but in whom additional recombinant FGF-2 had been added to the culture for 3 days in week 2 (10% serum/FGF-2). At the end of the culture period some cells were dissolved from alginate and immunostained for FGF-2 as before (A). The remainder of cells were made in to alginate plugs as before. Plugs were either left untreated (C), stimulated with FGF-2 (100 ng/ml), or were loaded for 2 min (0.01 MPa, 0.5 Hz). Cell lysates were immunoblotted for phosphorylated and total ERK as before (B). A B C C C C C Fig. 8 . Protein tyrosine phosphorylation upon chondrocyte loading is mainly FGF-2 dependent. Chondrocytes were extracted from articular cartilage, encapsulated into alginate beads, and cultured in 10% serum for 4 weeks. Forty-eight hours prior to loading some beads were incubated with SB402451 (250 nM). Beads were made into plugs on the day of the experiment as described above. Plugs were treated with either serum-free medium (C), IL-1 (100 ng/ml), FGF-2 (100 ng/ml), or were loaded (0.01 MPa, 0.5 Hz). After 15 min plugs were dissolved with EDTA on ice and lysed. Lysates were run on 12.5% sodium dodecyl sulphate page, then immunoblotted with an anti-phosphotyrosine antibody (1:3000) (A). The blots were stripped and reprobed first for phosphorylated ERK (B), then total ERK (C).
Control
an applied force. Disruption of this layer early in OA might conceivably impair tissue responses to normal mechanical loading.
Unlike that in the growth plate, where 75% of GAG chains on perlecan are chondroitin sulphate 28 , perlecan in articular cartilage (both young pig and human) is predominantly substituted with heparan sulphate (data not shown), and it is upon these GAG chains that FGF-2 is bound. Other cell surface HSPGs such as CD44 and members of the syndecan and glypican family, are expressed in articular chondrocytes 29 , but we found no evidence for other abundant HSPGs apart from perlecan.
The sequestration of FGF-2 on perlecan within a few microns of the cell surface makes it ideally placed to initiate a rapid signalling response upon loading. (ERK activation upon loading explants occurs within 2 min 7 ). This might occur as a result of release of FGF-2 from the matrix, either detached or attached to HS, or exchange of FGF-2 from perlecan to cell surface HSPGs. Alternatively, the close proximity may allow presentation of FGF-2 to the FGF cell surface receptor whilst still attached to perlecan. Perlecan and heparan sulphate have been shown to be co-factors for FGF receptor tyrosine kinase activation 30e33 , so it is tempting to speculate that in addition to sequestering FGF-2, perlecan may directly participate in the signalling response upon loading. We hypothesise that in resting, unloaded cartilage FGF-2 is held back from the cell surface thereby preventing signal transduction through the FGF receptor, but upon mechanical deformation of the matrix, FGF-2 is presented to the cell surface receptor with bound heparan sulphate, to activate down stream signalling pathways.
The cyclic loading used in these experiments results in a significant time-averaged creep compression by the end of the 2-min loading protocol (25% for alginate, 5% for explants). It may be that the ERK activation upon loading is the result of the net static strain that occurs by the end of the loading period. It is not clear whether the cyclic component of the load or the specific loading frequency determines the tissue response.
FGF-2 has been implicated as a mechanotransducer in other tissues. It was released by cultured adult rat ventricular myocytes in response to increased mechanical pressure 34 , and by human skeletal muscle cells in response to mechanical strain and sarcolemmal injury 35 . When smooth muscle cells encapsulated in a 3D collagen gel were subjected to a single compressive load a three fold increase in thymidine incorporation occurred, which was inhibited by neutralising antibodies to FGF-2 but not to plateletderived growth factor 36 . Pintucci et al. have described an FGF-dependent activation of ERK in confluent monolayer endothelial cells wounded with a razor blade. Blocking this response with neutralising antibodies to FGF-2 blocked endothelial cell migration 37 . In order to address from which location stored FGF-2 was liberated, Cheng et al. 38 measured its release from cultured vascular endothelial cells in response to mechanical strain. They determined that most of the release was from intracellular rather than HS bound stores.
Our results in alginate encapsulated chondrocytes are at variance with the conclusions from the above studies in other cell types. We have found that chondrocytes in alginate lay down pericellular matrix upon which FGF-2 binds, and in instances where little pericellular FGF-2 exists, ERK responses to mechanical loading are attenuated. It is possible that there may be additional release from intracellular FGF-2 stores upon loading, but the most likely interpretation of the data is that the pericellular pool, rather than release of intracellular growth factor, mediates FGF-2 dependent mechanotransduction in cartilage.
Finally, are integrins required for FGF mediated mechanotransduction in articular cartilage? As many tyrosine kinase growth factor receptors are closely linked to integrins on the cell surface and cooperate with growth factor signalling 39, 40 , it is possible that they modulate FGFR signal transduction upon loading. Our results suggest that most protein tyrosine phosphorylation upon loading is FGF-2 dependent, although FGF-independent protein phosphorylation (at 150 kDa) indicates the possibility of additional pathway activation. Whether this is mediated by integrin ligation is currently unknown.
